Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2019 18:20 ET | Source: NOVARTIS FINANCE S.A.

Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care

Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline...
April 24, 2019 01:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by...
March 26, 2019 19:35 ET | Source: NOVARTIS FINANCE S.A.

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients...
March 22, 2019 02:00 ET | Source: NOVARTIS FINANCE S.A.

Novartis plans for Alcon spin-off on April 9, 2019

Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange...
March 14, 2019 02:15 ET | Source: NOVARTIS FINANCE S.A.

Novartis announces change in Sandoz leadership

Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced...